Alovudine (MIV-310) |
|
Therapy Area
An NRTI for treatment of HIV patients.
|
Competitive Edge
Striking activity against multiresistant HIV in phase II studies, including in very low doses. Synergistic anti-HIV effect with AZT and antagonistic toxicity with AZT. |
Licensee
Noken Pharmaceuticals for the Chinese market. |
|
|
Last Modified: 12/05/2009
|
|
